Xenetic Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Xenetic Biosciences Inc (XBIO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Xenetic Biosciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 390,098M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-19.0% annualized vs trailing 12 months), vs holding steady (+1.1%) for its tracked peer group.
- Growth: Xenetic Biosciences Inc generated 12.0% revenue growth year over year in Q2 2026, vs 6.3% for its competitors combined.
- Profitability: Its -140.7% net margin compares with 9.6% for the peer group.
- Scale: Xenetic Biosciences Inc ranks #421 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Xenetic Biosciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $1.63M compares with $1.02M for the peer group (1.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
XBIO Sales vs. its Competitors, Q2 2026
Xenetic Biosciences Inc reported revenue growth of 11.99 % year on year in Q2 2026, above its competitors' combined revenue growth of 6.34 %.
With a net margin of -140.73 %, Xenetic Biosciences Inc reported lower profitability than its competitors (9.63 %).
Xenetic Biosciences Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Xenetic Biosciences Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Xenetic Biosciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Xenetic Biosciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Xenetic Biosciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Xenetic Biosciences Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 12.0% for Xenetic Biosciences Inc. Xenetic Biosciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Xenetic Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Xenetic Biosciences Inc | No | Yes | Yes | No |
| Competitors combined (96) | ||||
| Similar-Size Competitors (10) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
XBIO Stock Performance relative to its Competitors
XBIO Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Xenetic Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Xenetic Biosciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Xenetic Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Xenetic Biosciences Inc |
4.13 | 3.26 |
 Akari Therapeutics Plc |
846,737.51 | - |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Merck and Co Inc |
365,658.80 | 66,569.00 |
 Astrazeneca Plc |
291,719.12 | 58,739.00 |
 Amgen Inc |
254,015.58 | 38,903.00 |
| SUBTOTAL | 3,475,377.13 | 543,136.35 |
Sign in to see all competitors of Xenetic Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Xenetic Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Xenetic Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Xenetic Biosciences Inc .
Xenetic Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Xenetic Biosciences Inc | 4 | 1,630,389 | -1,237,546 |
| Akari Therapeutics Plc | 846,738 | - | -4,674,667 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Merck and Co Inc | 365,659 | 887,587 | 42,267 |
| Astrazeneca Plc | 291,719 | 706,847 | 123,141 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| PEERS TOTAL | 3,475,373 | 1,021,497 | 132,991 |
Sign in to see all peers for Xenetic Biosciences Inc .
Xenetic Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Xenetic Biosciences Inc .
Xenetic Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Xenetic Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Xenetic Biosciences Inc ranks #421 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,038 | 23.96 % |
| 2 | Johnson and Johnson | 685,131 | 12.82 % |
| 3 | Abbvie Inc | 520,479 | 9.74 % |
| 4 | Merck and Co Inc | 365,659 | 6.84 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 421 | Xenetic Biosciences Inc | 4 | 0.00 % |
Market cap and industry share for the rest of Xenetic Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Xenetic Biosciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 416 | Psyence Biomedical ltd | 4 | -96.85 % |
| 417 | Bio Green Med Solution Inc | 4 | - |
| 418 | Acurx Pharmaceuticals inc | 4 | -77.38 % |
| 419 | Cadrenal Therapeutics Inc | 4 | -88.84 % |
| 420 | Alaunos Therapeutics Inc | 1,234 | 12.3% |
| 421 | Xenetic Biosciences Inc | 4 | -28.88 % |
| 422 | Imunon Inc | 1,234 | 12.3% |
| 423 | Xortx Therapeutics inc | 1,234 | 12.3% |
| 424 | Rain Enhancement Technologies Holdco Inc | 1,234 | 12.3% |
| 425 | Gelteq Limited | 1,234 | 12.3% |
| 426 | Traws Pharma inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Xenetic Biosciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Xenetic Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | 1.2x | 4.2x | -3.1x |
| Return on Equity | -0.41 % | industry aggregate | -16.76 % |
| Return on Invested Capital | - | -9.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Xenetic Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 295.17 % | 42.71 % | 48.81 % | -1.56 % | 19.04 % |
| Operating Margin | - | - | -3,189.82 % | 295.77 % | -393.57 % | - | - | -95.23 % |
| Return on Invested Capital | -27.61 % | -40.76 % | -51.04 % | 11.65 % | -22.29 % | -19.88 % | -28.83 % | -27.09 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Xenetic Biosciences Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Xenetic Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.3% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Xenetic Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 988 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Xenetic Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Xenetic Biosciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Xenetic Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Xenetic Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 16.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-19.0% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (51.10 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Xenetic Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Xenetic Biosciences Inc | 1.87 | 6.96 | - |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
Sign in to see all peers for Xenetic Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Xenetic Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Xenetic Biosciences Inc | Q2 2026 | +12.0 % | - |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| PEERS TOTAL | +8.0 % | -0.6 % |
Sign in to see all peers for Xenetic Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Xenetic Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Xenetic Biosciences Inc | Q2 2026 | - | - |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
Sign in to see all peers for Xenetic Biosciences Inc .
Xenetic Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Xenetic Biosciences Inc | - | - | - |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
Sign in to see all peers for Xenetic Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Xenetic Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Xenetic Biosciences Inc | - | 1.27 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 42.48 | 6.92 |
| Merck and Co Inc | 119.39 | 5.49 |
| Astrazeneca Plc | 28.56 | 4.97 |
| Amgen Inc | 26.97 | 6.53 |
| PEERS AVERAGE | 49.15 | 6.40 |
Sign in to see all peers for Xenetic Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.